'Aint She Rich Enuf?': Serena Williams Under Fire as the FDA Steps In Following 'Misleading' Commercial for Migraine Medicine Maker
A migraine medicine once-endorsed by Serena Williams has come under fire amid claims advertisements oversold it’s usefulness. Last month, on Aug. 29, the Food and […]
FDA sends letter to drugmaker, says ad featuring Serena Williams was misleading
A drugmaker's advertisement featuring Serena Williams is under FDA scrutiny for misleading claims that it can quickly cure migraine headaches.
FDA calls out AbbVie over ‘misleading’ commercial featuring Serena Williams
The U.S. Food and Drug Administration is taking North Chicago-based drugmaker AbbVie to task, warning in a recent letter that a migraine medication commercial featuring Serena Williams is “misleading.
FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams
The FDA has scolded AbbVie for making false and misleading claims about a TV ad about a migraine pill that features Serena Williams.
FDA takes action against Abbvie for misleading Ubrelvy ad with Serena Williams
The Food and Drug Administration recently intervened regarding a migraine medication ad featuring tennis superstar Serena Williams.
FDA slams AbbVie for misleading claims in Serena Williams ad for migraine drug Ubrelvy
The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena Williams that went out of bounds with claims about how quickly the product relieves symptoms.
AbbVie faulted for misleading ad featuring Serena Williams
In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk show dressing room, which resolves by the time she walks onto the set and allows her to carry out the interview laughing and pain-free.
UPI20d
Migraine drug Ubrelvy may stop headaches at first sign
People who took ubrogepant (Ubrelvy) were 73% more likely to say they had no disability and were able to function normally within a couple of hours, compared to those who took a placebo ...
clinicaltrialsarena12d
Migraine market expected to reach $16.4bn across 7MM by 2033
The migraine market across the 7MM is poised to grow at a compound annual growth rate (CAGR) of 6.0% from $9.2bn in 2023 to ...
Healthline15d
Ubrelvy: Pregnancy and Breastfeeding Information
Ubrelvy (ubrogepant) is a prescription oral tablet that’s used for fast-acting relief of migraine symptoms in adults. Ubrelvy may not be safe to take while pregnant or breastfeeding. If you can ...
FiercePharma8d
AbbVie's Ubrelvy to be top migraine seller in 2033
AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the ...